Clinical Trial Results: A Safety and Immunogenicity of Intranasal Nanoemulsion Adjuvanted Recombinant Pandemic Flu Vaccine in Healthy Adults [Phase 1]

View source ↗

Summary

Phase 1 trial report on safety and immunogenicity of an intranasal nanoemulsion adjuvanted recombinant pandemic influenza vaccine in healthy adults.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pandemic Influenza

Drugs mentioned

• Intranasal Nanoemulsion Adjuvanted Recombinant Pandemic Flu Vaccine

Snippet

Sponsor: BlueWillow Biologics | Conditions: Influenza, Pandemic | Phase 1 | Status: COMPLETED | Results posted: 2026-07-30